Skip to main content
Clinical Trials/NCT03420131
NCT03420131
Unknown
Not Applicable

DETErmining the funCTional Significance of Intermediate Stenoses in isCHEMIc heArt Disease (DETECT ISCHEMIA): Diagnostic Agreement of iFR and QFR.

Contilia Clinical Research Institute1 site in 1 country250 target enrollmentJuly 18, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fractional Flow Reserve, Myocardial
Sponsor
Contilia Clinical Research Institute
Enrollment
250
Locations
1
Primary Endpoint
QFR- iFR diagnostic grey zone calculation.
Last Updated
8 years ago

Overview

Brief Summary

A Prospective, observational, single center diagnostic study to investigate the the diagnostic agreement between QFR and the pressure wire-based iFR in a real world setting.

Detailed Description

During coronary angiography, intermediate stenoses can not be adequately assessed by visual assessment alone. It is necessary to evaluate the functional significance to guide their treatment. Fractional Flow Reserve (FFR) is the current gold standard for determining this functional significance but its adoption in clinical practice remains low. The instantaneous wave-free ratio (iFR) is an alternative way to determine the flow-limiting characteristics of a coronary stenosis with a pressure wire but without the need to induce hyperemia. Large randomised trials have confirmed the non-inferiority of iFR in respect to FFR in terms of outcome. Quantitative Flow Ratio (QFR) is another new method for evaluating the functional significance of coronary stenosis It is a software-based analysis of conventional angiographic images to estimate the pressure drop caused by a coronary stenosis. The diagnostic agreement with FFR seemed promising in the FAVOR Pilot Study and a larger trial is enrolling for confirmation. A stepwise approach of QFR and iFR could make the functional assessment of intermediate stenoses more practical and cost-effective. However before being used as a combination in daily practice, QFR has to be validated in respect to iFR. The primary objective of the trial is to investigate the diagnostic agreement between QFR and the pressure wire-based iFR in a real world setting

Registry
clinicaltrials.gov
Start Date
July 18, 2017
End Date
October 1, 2018
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Contilia Clinical Research Institute
Responsible Party
Principal Investigator
Principal Investigator

Christoph Jensen, MD Associate Prof.

Christoph Jensen, MD, Associate Professor of medicine

Contilia Clinical Research Institute

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 with symptoms of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing, abnormal noninvasive testing)
  • Patients witch semi recent (\>3 days) acute coronary syndromes can be included but only for the non-culprit vessels and outside of primary intervention during acute myocardial infarction.
  • Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
  • Eligible for coronary angiography and/or percutaneous coronary intervention
  • Coronary artery disease with at least 1 or more visually assessed de novo coronary stenosis (30-90% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram.
  • Exclusion criteria:
  • Contraindication to adenosine administration
  • Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

QFR- iFR diagnostic grey zone calculation.

Time Frame: 1 hour

QFR limits for achieving 95% sensitivity and specificity in comparison to iFR

Diagnostic performance of QFR in comparison to iFR

Time Frame: 1 hour

reported as sensitivity, specificity, positive and negative likelihood ratio of QFR according to iFR

Secondary Outcomes

  • Diagnostic performance of QFR in comparison to FFR(1 hour)
  • Diagnostic performance of iFR in comparison to FFR(1 hour)
  • iFR- FFR diagnostic grey zone calculation.(1 hour)
  • Effect of p20-DAC2 score in proximal and mid-LAD stenosis on QFR-iFR-FFR disagreement.(1 hour)
  • QFR- FFR diagnostic grey zone calculation.(1 hour)
  • effect of 3D QCA characteristics on QFR-iFR-FFR disagreement.(1 hour)
  • Effect of lesion location on QFR-iFR-FFR disagreement.(1 hour)

Study Sites (1)

Loading locations...

Similar Trials